As per our report, the global transfection reagents and equipment market size was worth USD 1027.03 million in 2024. It is expected to grow at a CAGR of 7.5 % to reach USD 1474.44 million by 2029.
The growing need for biopharmaceuticals worldwide majorly propels the transfection reagents and equipment market growth. The demand for biopharmaceuticals is constantly growing worldwide. The popularity of biopharmaceuticals has increased significantly in recent years due to their high specificity and low toxicity. Transfection reagents and equipment tools are used in the manufacturing of biopharmaceuticals to introduce foreign DNA or RNA into cells to produce therapeutic proteins or antibodies. The demand for transfection reagents and equipment is expected to grow with the increasing need for biopharmaceuticals in the coming years and boost the market growth.
The growing demand for gene therapy drives the transfection reagents and equipment market growth. The usage of gene therapy has increased significantly in recent years to treat various genetic disorders and diseases such as inherited genetic disorders, cancer and viral infections. Transfection is an essential step in the process of gene therapy. The benefits of gene therapy have been recognized in several countries in recent years and many pharmaceutical companies have been investing notable amounts in R&D to develop new gene therapies and treatments that rely on transfection. The demand for gene therapy is expected to grow substantially in the coming years and drive demand for transfection reagents and equipment and contribute to the market growth.
The growing patient population of chronic diseases, rapidly growing biotechnology and pharmaceutical industries, rising usage of transfection reagents and equipment in various applications such as drug discovery and development, diagnostic assays, and research reagents, rising adoption of personalized medicine, and increasing penetration of technological advancements in transfection equipment boost the growth rate of the market. The growing investments from governmental and non-governmental organizations in the life sciences industry including gene therapy and personalized medicine and rising demand for CRISPR/Cas9 gene editing further fuel the growth rate of the market.
Extraction of DNA & RNA by transfection reagents & equipment is very costly and can hamper the global transfection reagents and equipment market growth. High costs associated with transfection reagents and equipment are one of the major factors hampering the market growth. Limited cell type compatibility, toxicity of transfection reagents, low transfection efficiency and the scarcity of technical expertise hinder the market growth. The stringent regulatory environment, competition from other alternative technologies such as electroporation and viral vectors and the limited shelf life of some of the transfection reagents and equipment further inhibits the market’s growth rate.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Analysed |
By Product, Type, Route of Administration, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
Market Leaders Profiled |
Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. |
Based on product, the reagents segment had the leading share of the global transfection reagents and equipment market in 2022 and is expected to register a healthy CAGR during the forecast period. The rising interest in gene therapy for the treatment of genetic disorders and other diseases, the increasing patient population of cancer and advancements in transfection technologies majorly drive the segmental growth. The growing availability of funding from governments, private foundations and pharmaceutical companies for transfection reagents to use in R&D and the growing number of research activities in fields such as cell biology, immunology and neuroscience further contribute to the growth rate of the segment.
The instruments segment is anticipated to witness the highest CAGR in the global market during the forecast period due to the growing demand for high throughput screening in drug discovery and development, increasing number of advancements in transfection instrumentation and rising demand for cell-based assays in drug discovery and development.
Based on the method, the biochemical segment accounted for the largest share of the worldwide market in 2022 and is predicted to register a healthy CAGR during the forecast period. The growing use of biochemical methods by researchers due to their high transfection efficiency is one of the key factors propelling segmental growth. The lower toxicity of biochemical methods compared to other methods, such as viral transfection is another major factor contributing to the segmental growth. Biochemical methods are not complex to use and do not require specialized equipment or technical expertise and due to these, many researchers prefer biochemical methods compared to the others and this trend is likely to continue during the forecast period and drive the segmental growth.On the other hand, the viral segment is estimated to grow at the highest CAGR during the forecast period due to its high efficiency and specificity. The growing use of viral transfection in gene therapy further contributes to segmental growth.
Based on the application, the biomedical research segment is expected to hold the leading share of the global transfection reagents and equipment market during the forecast period. The growing number of research activities in fields such as cell biology, immunology, and neuroscience, the rising demand for gene therapy and the increasing patient count of chronic diseases worldwide fuel the segmental growth. The advancements in the gene editing technologies such as CRISPR-Cas9, growing investments for biomedical research from governments, academic institutions and private companies and the trend towards personalized medicine further contribute to the segmental growth.
Based on end-user, the academic & research institutes segment is estimated to hold the leading share of the global market during the forecast period due to the growing funding from the governments of several countries for research activities and advancements in research technologies. The growing number of collaborations between academic institutes and research organizations and the rising need to develop new treatment options for several diseases further contribute to segmental growth.
On the other hand, the pharmaceutical & biotechnologies segment is estimated to grow at the highest CAGR during the forecast period. The availability of investments for R&D by the pharmaceutical and biotechnological companies, the rising need for innovative drug delivery methods, the increasing number of contract research and manufacturing organizations (CROs/CMOs) and the growing number of regulatory approvals for new drugs and therapies drive the segmental growth.
Geographically, the North American transfection reagents and equipment market held the leading share of the global market in 2022 and the regional domination is estimated to continue during the forecast period. The presence of leading biotech clusters such as the San Francisco Bay Area, Boston-Cambridge and San Diego that attract investment and foster innovation in the life sciences is one of the key factors contributing to the regional market growth. The high healthcare expenditure, the presence of robust healthcare infrastructure and rising emphasis on precision medicine and genetic testing in North America propel the North American market growth. Furthermore, growing focus on the use of biologics in drug development, well-established regulatory frameworks for biologics and gene therapies, high adoption rate of advanced research technologies and rising prevalence of cancer and genetic disorders boost the growth rate of the North American market. The U.S. captured the leading share of the North American market in 2022 and is expected to register a healthy CAGR during the forecast period owing to the increasing healthcare spending, growing cancer patient population and rapidly growing biotechnology industry.
The Asia-Pacific transfection reagents and equipment market is anticipated to register the fastest CAGR during the forecast period among all the regions due to factors such as the rapidly expanding biotechnology industry, particularly in China and India, growing population, increasing healthcare expenditure and increasing emphasis on developing new treatments for infectious diseases, such as COVID-19. The growing number of advancements in healthcare infrastructure, rising adoption of advanced research technologies, increasing demand for biopharmaceuticals and biosimilars and increasing number of government initiatives and funding programs to support biotech and life sciences research further boost the growth rate of the APAC market. China led the market in the Asia-Pacific region in 2022 and India is expected to showcase a healthy CAGR during the forecast period.
The Europe transfection reagents and equipment market was the second biggest regional market for transfection reagents and equipment worldwide in 2022 and is expected to account for a substantial share of the worldwide market during the forecast period. Factors such as the growing emphasis on promoting innovation through public-private partnerships and collaborations, increasing demand for biopharmaceuticals and biosimilars, expansion of the European Union, increasing opportunities for research and development and strong regulatory frameworks for drug approval and clinical trials primarily drive the European market growth. The rising prevalence of lifestyle diseases such as obesity and diabetes and an increasing number of contract research organizations (CROs) and contract manufacturing organizations (CMOs) further propel the European market growth. Germany captured the leading share of the European market in 2022.
The Latin America transfection reagents and equipment market occupied a considerable share of the worldwide market in 2022 and is anticipated to grow at a healthy CAGR during the forecast period. The rising demand for innovative therapeutics to treat infectious diseases, the rapidly growing pharmaceutical industry in the Latin American region, increasing investments for R&D in life sciences and the expansion of clinical trial activities in the Latin American region drive the Latin American market growth.
The MEA transfection reagents and equipment market held a moderate share of the worldwide market in 2022. However, the MEA market is expected to register a steady CAGR during the forecast period due to the rising demand for new treatments for infectious diseases, such as HIV/AIDS and malaria, expansion of the pharmaceutical industry in the region, advancements in the research infrastructure, particularly in the Gulf Cooperation Council (GCC) countries and emphasis on public-private partnerships to drive innovation.
Major companies in the global transfection reagents and equipment market profiled in the report are Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands), Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc. (U.S.).
These companies hold a leading position in the transfection reagent and equipment market because of their well-established presence in the fields of genomics, spanning fifty countries, heavy R&D investments, and strong sales as well as distribution force.
On October 10, 2019, Nuvec Pharma developed the DNA & RNA Transfection technology using silica nanoparticles with irregular surface. It can trap and protect the nucleic acid during cell formation. The nucleic acid transfection technology responds to the T-cells; this is necessary to kill cancer cells or viruses.
This research report on the global transfection reagents and equipment market has been segmented based on the product, route of administration, and region.
By Product
Reagents
By Method
By Application
By End User
By Region
Frequently Asked Questions
The global transfection reagents and equipment market is predicted to be worth USD 955.38 million in 2023.
The growing research and development activities in the field of life sciences, the growing prevalence of genetic disorders and chronic diseases, and rising demand for gene therapy and genetic engineering majorly drive the transfection reagents and equipment market growth.
High cost of equipment, safety concerns related to viral-based transfection, and variability in transfection efficiency are some of the major challenges to the transfection reagents and equipment market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region